Prognostic implications of genotype findings in non-ischemic dilated cardiomyopathy: a network meta-analysis

European Heart Journal

28 October 2024
Organised by: Logo
ESC Journals

Abstract

AbstractBackground

Evidence on the relative impact of diverse genetic backgrounds associated with non-ischemic dilated cardiomyopathy (DCM) remains contradictory.

Aim

This study sought to synthesize the available data regarding long-term outcomes of different gene groups in DCM.

Methods

Electronic databases were systematically screened to identify studies reporting prognostic data on pre-specified gene groups. Those included pathogenic/likely pathogenic (P/LP) variants, truncating titin variants (TTNtv), lamin A/C mutations (LMNA), and desmosomal proteins. Outcomes were divided into composite adverse events (CAEs), major ventricular arrhythmic events (MVAEs) and heart failure events (HFEs). Random effects meta-analyses were conducted to quantify the pooled odds ratio (ORs) for each gene group. A frequentist network meta-analysis was executed to allow indirect within-gene group comparisons.

Results

Twenty-six studies comprising 7,255 genotyped DCM individuals were included. Patients with P/PL variants had a higher risk for CAEs [OR, 2.10 (95% CI, 1.67-2.65)], MVAEs [OR, 1.86 (95% CI, 1.52-2.26)], and HFEs [OR, 2.01 (95% CI, 1.08-3.73)] than genotype negative patients. The presence of TTNtv was linked to a higher risk for CAEs [OR, 1.78 (95% CI, 1.20-2.63)], but not MVAEs or HFEs. LMNA and desmosomal groups suffered a higher risk for CAEs, MVAEs, and HFEs compared to non-LMNA and non-desmosomal groups respectively (Picture 1). When genes were indirectly compared, the presence of LMNA resulted in a more detrimental effect that TTNtv, with respect to all composite outcomes but no significant difference was found between LMNA and desmosomal genes. Desmosomal genes harbored a higher risk for MVAEs compared to TTNtv (Picture 2).

Conclusion

Different genetic substrates associated with DCM result in divergent natural histories. Routine utilization of genetic testing should be employed to refine risk stratification and inform therapeutic strategies in DCM.

Natural history of DCM based on genotype

Network meta-analysis of gene variants

Contributors

V Anastasiou
V Anastasiou

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece

A S P Papazoglou
A S P Papazoglou

Author

Naval Hospital of Athens Athens , Greece

T Z Zegkos
T Z Zegkos

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece

S D Daios
S D Daios

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece

D V M Moysidis
D V M Moysidis

Author

University Hospital Zurich Zurich , Switzerland

D P Parcharidou
D P Parcharidou

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece

G T Tziomalos
G T Tziomalos

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece

S K Katranas
S K Katranas

Author

Private Practice in Thessaloniki Thessaloniki , Greece

P R Rouskas
P R Rouskas

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece

T K Karamitsos
T K Karamitsos

Author

Aristotle University of Thessaloniki Thessaloniki , Greece

A Z Ziakas
A Z Ziakas

Author

AHEPA General Hospital of Aristotle University Thessaloniki , Greece